Company news
Abeona Therapeutics Inc. news in 2022
Abeona Therapeutics Inc.'s news releases, calls and decks from 2022, newest first.
Abeona Therapeutics Reports Third Quarter 2022 Financial Results
November 13, 2022
Abeona Therapeutics Announces Positive Topline Results with Both Co-Primary Endpoints Met in Pivotal Phase 3 VIITAL™ Study of EB-101
November 2, 2022
Abeona Therapeutics Announces $35 Million Private Placement Financing
November 2, 2022
Abeona Therapeutics Announces Database Lock for Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)
October 18, 2022
Abeona Therapeutics Announces Completion of Patient Follow-up in Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)
October 3, 2022
Abeona Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit
September 21, 2022
Abeona Therapeutics to Participate in the Cantor Fitzgerald Cell and Genetic Medicines Conference
September 12, 2022
Abeona Therapeutics Reports Second Quarter 2022 Financial Results
August 10, 2022
Abeona Therapeutics Regains Compliance with Nasdaq Listing Requirements
July 19, 2022
Abeona Therapeutics Granted Second 180-Day Period by Nasdaq to Regain Compliance with Minimum Bid Price Rule
May 18, 2022
Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome Type A (MPS IIIA) from Abeona Therapeutics
May 16, 2022
Abeona Therapeutics Reports First Quarter 2022 Financial Results
May 12, 2022
Abeona Therapeutics Announces AAV204, a Novel AAV Capsid, Demonstrated Robust Macular Transduction Following Para-Retinal Administration in Non-Human Primates
May 3, 2022
Abeona Therapeutics Announces Pricing of $25 Million Private Placement of Convertible Redeemable Preferred Stock
April 28, 2022
Abeona Therapeutics Announces Presentation at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
April 28, 2022
Abeona Therapeutics Announces Strategy Update and 2021 Financial Results
March 30, 2022
Abeona Therapeutics to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit
March 27, 2022
Abeona Therapeutics Achieves Target Enrollment in Pivotal Phase 3 VIITAL™ Study of EB-101 in RDEB
March 13, 2022
Calls in 2022
Decks in 2022
- Technical Presentation (November 2022)
Technical · 26 slides · Nov 3, 2022